Compass Pathways (NASDAQ:CMPS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Compass Pathways (NASDAQ:CMPS) from a strong sell rating to a sell rating in a research note published on Tuesday morning,Wall Street Zen reports.

Other research analysts have also recently issued research reports about the stock. Canaccord Genuity Group lifted their target price on shares of Compass Pathways from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, June 26th. Morgan Stanley increased their target price on Compass Pathways from $17.00 to $18.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. UBS Group set a $18.00 target price on Compass Pathways in a research note on Thursday, May 7th. Stifel Nicolaus boosted their price target on Compass Pathways from $14.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Finally, HC Wainwright dropped their price target on Compass Pathways from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Compass Pathways currently has an average rating of “Moderate Buy” and a consensus price target of $23.36.

Compass Pathways Trading Up 0.5%

Shares of NASDAQ:CMPS opened at $13.29 on Tuesday. Compass Pathways has a 12-month low of $4.68 and a 12-month high of $15.40. The company has a market cap of $1.84 billion, a PE ratio of -2.88 and a beta of 2.54. The stock has a 50 day moving average of $13.13 and a 200 day moving average of $10.32. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($1.49). As a group, equities research analysts expect that Compass Pathways will post -1.26 EPS for the current year.

Hedge Funds Weigh In On Compass Pathways

Institutional investors have recently added to or reduced their stakes in the company. Ancora Advisors LLC bought a new stake in Compass Pathways in the 2nd quarter worth approximately $43,000. EverSource Wealth Advisors LLC boosted its position in shares of Compass Pathways by 67.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after acquiring an additional 1,920 shares during the last quarter. Persistent Asset Partners Ltd purchased a new position in shares of Compass Pathways in the fourth quarter valued at $38,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Compass Pathways in the fourth quarter valued at $47,000. Finally, Advisory Services Network LLC bought a new stake in Compass Pathways in the third quarter worth $41,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.